This latest twist in the Lykos Therapeutics saga threatens A serious overhaul of the company’s tactic and path, with Musk ally and billionaire investor Antonio Gracias appearing to need to get the corporation back again towards its nonprofit drug advancement roots and a more Doblinite philosophy.One of several critical functions in the Portal cop